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Primary skeletal neoplasms account for 0,2% of human 
tumors, whereas involvement of skeletal tissue by 
metastatic disease is much more common. Their soft 
tissue-related counterparts outnumber bone tumors by a 
margin of approximately 10:1. Because of their rarity, 
not much is known about the etiology and risk factors 
of bone tumors, although a difference in ethnical 
distribution has been observed.  
Bone tumors are mostly of mesenchymal origin, though 
for example Ewing sarcoma is thought to have 
neuroectodermal precursor cells. Classification of the 
World Health Organization will be followed in this 
overview. Grading of bone tumors is roughly based on 
the cellularity of the lesion compared to the amount of 
extracellulair matrix, nuclear features, the presence of 
mitotic figures and necrosis. Staging via the TNM 
system is normally not used, because metastases in 
lymph nodes are not frequent in these lesions. 
Therefore staging is based on degree of differentiation 
of the tumor tissue and local and distant spread of the 
tumor. Genetic information and references are provided 
for tumors investigated in more than a single case. 
Classification 

























High grade surface 
Fibrogenic tumors  
Desmoplastic fibroma of bone 
Fibrosarcoma of bone 
Fibrohistiocytic tumors 
Histiocytoma of bone 
Ewing sarcoma/Primitive neuroectodermal tumor 
Giant cell tumors 




Haemangioma and related lesions 
Angiosarcoma 
Myogenic, lipogenic, neural and epithelial tumors 
Leiomyosarcoma of bone 
Lipoma of bone 
Adamantinoma and osteofibrous dysplasia 
Tumors of undefined neoplastic nature 
Aneurysmal bone cyst 
Simple bone cyst 
Fibrous dysplasia 
Langerhans cell histiocytosis (LCH) 
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Clinics and pathology 
Cartilage tumors 
Osteochondroma 
Germ line mutations in the tumorsupressor genes 
Exostosin-1 (EXT-1) located at 8q24 and Exostosin-2 
(EXT-2) located at 11p11-p12 have been found in 
hereditary multiple osteochondromas (MO). Somatic 
mutations are extremely rare in these tumors. In four 




By conventional cytogenetic analysis, abnormalities 
involving chromosome 6 and the long arm of 
chromosome 12 have been detected.  
- Periosteal chondroma 
This subtype has not been individually investigated.  
Chondroblastoma 
Although a dozen of case reports have been published, 
no specific alterations were found in these rare benign 
tumors. 
Chondromyxoid fibroma 
Structural rearrangements of chromosome 6 are found 
to be non-random, particularly involving the long arm 
(q13 and q25) and p25 on the short arm.  
Chondrosarcoma 
In most genetic studies no difference is made between 
peripheral, central chondrosarcoma and other subtypes. 
CGH revealed extensive genetic aberrations; gains of 
whole chromosomes or chromosome arms at 20q (32-
38%), 20p (24-31%), and 14q23-qter (24-28%). 
In a comparative study, 19 of 20 peripheral 
chondrosarcoma showed LOH at the loci for EXT, 
EXTL, 13q14, 17p14, 17p13, 9p21 and chromosome 
10, while only 3 of 12 central chondrosarcoma did. In 
addition the ploidy status in peripheral chondrosarcoma 
showed wide variation (0,56-2,01), whereas central 
chondrosarcomas were predominantly periploid. 
- Dedifferentiated 
In the cartilaginous, as well as in the dedifferentiated 
part of the tumor an identical somatic 6 bp deletion in 
exon 7 of p53 and loss of the same copy on 
chromosome 13 had been found. These findings 
provide evidence for a common origin of both parts.  
- Mesenchymal 
A Robertsonian (13; 21) translocation,  
der(13;21)(q10;q10), was detected in two cases, 
together with loss of material from chromosome 8 and 
20 and gain of material from chromosome 8. 
- Clear cell 






No specific alterations have been reported. 
Osteogenic tumors 
Osteoid osteoma 
Involvement of band 22q13 and loss of the distal part 
of arm 17q were detected in two out of three analyzed 
cases. 
Osteoblastoma 
No consistent aberrations have been detected in four 
cases, although clues are leading to deregulation of the 
cell cycle. No telomerase activity could be found. 
Osteosarcoma 
- Conventional 
Although most osteosarcomas reveal complex 
chromosomal aberrations, no specific alterations have 
been found. Amplification at 1q21-23 and 17p, together 
with co-amplification of 12q13-15 are frequently 
reported. In 14-27% of osteosarcomas, the MDM2 gene 
is amplified and in 41% the PRIM1 gene. 
Amplification of the CDK4 gene is found in aggressive 
lesions. Chromosome 12p is differently amplified in 
low- versus high-grade osteosarcomas. The MYC gene 
has been shown to be amplified in 44% of 
osteosarcoma (8q24). 
- Teleangiectatic 
In contrast to the conventional osteosarcomas, no 
amplifications were detected in four cases. Complex 
chromosomal changes were found. 
- Small cell 
No genetic alterations have been reported on this 
subtype of osteosarcoma. 
- Low grade central 
The complex aberrations found in high-grade 
osteosarcomas could not be identified in these low-
grade variants. Recurrent gains have been reported with 
minimal common regions at 12q13-14, 12p and 6p21. 
- Secondary 
In tumors developing in bone after radiation, 
chromosomal losses are more frequently observed than 
gains. Especially 1p, which is lost in 3% of the 
conventional type, is lost in 57% of the radiation-
associated type. 
In osteosarcomas secondary to Paget Disease of Bone 
(PDB) LOH is found at 18q, the locus for PDB. 
- Parosteal 
Ring chromosomes are reported as the sole alteration in 
parosteal osteosarcoma. Using FISH techniques, the 
SAS, CDK4 and MDM2 genes are shown to be co-
amplified with a minimal common region at 12q13-15 
in the ring chromosomes. 
- Periosteal 
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- High grade surface 
These lesions have not been studied as a specific 
subtype.  
Fibrogenic tumors 
Desmoplastic fibroma of bone 
Like in desmoid tumors, trisomies 8 and 20 are 
commonly found. 
Fibrosarcoma of bone 
No cytogenetic investigations on fibrosarcoma have 
been published. 
Fibrohistiocytic tumors 
Histiocytoma of bone 
Of the benign form of this tumor, no cytogenetic 
information is available. Its malignant counterpart 
shows LOH at chromosome 9p21-22, which has also 
been shown by CGH before. 
Ewing sarcoma/Primitive 
neuroectodermal tumor 
The most common rearrangement (85%) in this tumor 
is translocation t(11;22)(q24;q12). Consequently, this 
leads to the fusion protein EWS/FLI1. Other 
translocations found in the Ewing Sarcoma gene are 
listed below: 
 
Fusion of to translocation % 
EWS FLI1 t(11;22)(q24;q12) 85 
EWS ERG t(21;22)(q22;q12) 10-15 
EWS ETV1 t(7;22)(p22;q12) < 1 
EWS FEV t(2;22)(q36;q12) < 1 
EWS E1AF t(17;22)(q21;q12) < 1 
 
Giant cell tumors 
Reduction in length of the telomeres, as well as 
telomeric association, has been demonstrated in these 
tumors. Most commonly 11p, 13p, 14p, 15p, 19q, 20q 
and 21p are affected. 
Notochordal tumors 
Chordoma 
Nine of sixteen investigated chordomas were 
hypodiploid with a chromosome number ranging from 
33 to 44. Chromosomes 3, 4, 10, and 13 are most 
commonly lost, and in half of the cases the following 
segments are lost up to the telomere: 1p31, 3p21, 3q21, 
9p24, 17q11. Because LOH is found at band 1p36, a 
tumor suppressor gene is thought to exist on distal 1p. 
Vascular tumors 
Haemangioma and related lesions  




An identical translocation of chromosomes 1 and 3 has 
been reported in two epithelioid 
haemangioendotheliomas. 
Myogenic, lipogenic, neural and 
epithelial tumors 
Leiomyosarcoma of bone  
5 Grade IIB tumors demonstrated a rate of genomic 
loss of 90%, whereas high micro satellite instability 
was not observed. Allelotyping revealed loss of pRb in 
the tumors. In addition, chromosomal loss was noticed 
in human telomerase subunit-linked markers. 
Lipoma of bone  
Only one case study is published about the benign form 
of this tumor. On its malignant counterpart, 
liposarcoma of bone, no genetic information has been 
published. 
Adamantinoma and osteofibrous dysplasia 
Cumulating evidence indicates that classic 
adamantinomas derive from their osteofibrous 
dysplasia (OFD)-like counterparts. OFD and 
adamantinoma show common cytogenetic 
abnormalities. In 15 cases of adamantinoma (n=11) and 
OFD (n=4) trisomies of chromosomes 7, 8, 12, 19 and 
21 were detected. These findings further substantiate 
the clonal origin of OFD and the common histogenesis 
of OFD and adamantinoma. 
Tumors of undefined neoplastic nature 
Aneurysmal bone cyst  
Aneurysmal bone cysts can be primary or secondary to 
other bone lesions. Chromosome bands 16q22 and/or 
17p13 (USP6 gene) are non-randomly rearranged in 
ABC, regardless of tumor type (classic and solid) and 
of location (osseous and extraosseous). However, 
rearrangements are absent in secondary ABC. A 
recurrent t(16;17)(q22;p13) has been identified, but 
other chromosomal segments as translocation partner 
for each chromosome have been described. 
Simple bone cyst  
Only one case report describes structural 
rearrangements. 
Fibrous dysplasia  
Two fibrous dysplasia cases exhibited either a 
completely normal karyotype or single cell aberrations. 
Evidence that this lesion is neoplastic comes from the 
fact that clonal chromosomal aberrations have been 
found. In monostotic as well as polyostotic lesions 
activating GNAS1(20q13.2) mutations, known from 
the McCune-Albright syndrome, have been 
demonstrated. 
Langerhans cell histiocytosis (LCH)  
Studies of X-chromosome inactivation demonstrated 
that LCH is clonal. 
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Congenital and inherited syndromes 
Beckwith-Wiedemann syndrome  
This syndrome, which is caused by heterogenic genetic 
changes on 11q15, is subject to genomic imprinting. 3 
Beckwith-Wiedemann syndrome chromosome regions 
(BWSCR) have been identified: BWSC1 near 
INS/IGF2, BWSC2 5 Mb proximal to BWSC1, and 
BWSC3 2 Mb even more proximal. 
Enchondromatosis: Ollier disease and Maffucci 
syndrome 
These syndromes are non-hereditary although a case of 
familial clustering has been reported. Mutations in the 
PTH receptor 1 have been found in two cases, but these 
results could not be confirmed in a larger series of 31 
patients, suggesting that PTHR1 is not the culprit for 
enchondromatosis. 
McCune-Albright syndrome  
Mutations in the GNAS1 gene, located on 20q13, 
change the structure of the G-protein a-stimulatory 
subunit. Dysfunctions of the heterotrimeric G-protein 
complexes lead to this non-familial occurring disorder. 
Multiple osteochondromatosis (MO)/Hereditary 
Multiple Exostosis  
Mutations in one of the two exostosin (EXT) genes are 
responsible for this autosomal dominant syndrome. 
EXT1 is located at 8q24 and EXT2 at 11p11-p12. Most 
mutations are either nonsense, frame shift or splice-site 
mutations, leading to premature termination of the EXT 
proteins. This causes alteration of the gene products, 
which are functioning in the endoplasmatic reticulum 
as transmembrane glycoproteins, and will affect the 
biosynthesis of heparan sulphate proteoglycans, leading 
to altered growth factor signaling. 
Familial Paget Disease of Bone  
Familial Paget Disease of Bone (PDB) demonstrates 
linkage to chromosome 18q. Some cases (PDB type 2) 
are caused by mutations in the TNFRSF11A gene on 
chromosome 18q22.1, which encodes RANK, a protein 
essential in osteoclast formation. The phenotype linked 
to chromosome 5q35 (PDB type 3) is caused by 
mutations in the SQSTM1 gene, the product of which is 
associated with the RANK pathway. 
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